The preliminary results of the efficiency of Mcl-1-specific BH3 mimetic AMG-176 demonstrated moderate activity in 26 patients with relapsed or refractory multiple myeloma, in which 11 patients had stable disease as best overall response and 22 patients discontinued treatment due to progressive disease [44]. The gene discussed is MCL1; the disease is plasma cell myeloma.